Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus

Imagem de Miniatura
Arquivos
art_MACHADO_Role_of_Neutralizing_Antibodies_in_Adults_With_Community_2012.PDF (153.06 KB)
Citações na Scopus
52
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
LUCHSINGER, Vivian
PIEDRA, Pedro A.
RUIZ, Mauricio
ZUNINO, Enna
MARTINEZ, Maria Angelica
FASCE, Rodrigo
ULLOA, Maria Teresa
LARA, Pamela
Citação
CLINICAL INFECTIOUS DISEASES, v.54, n.7, p.905-912, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Respiratory syncytial virus (RSV) has been implicated in the etiology of adult community-acquired pneumonia (CAP). We investigated RSV infection in Chilean adults with CAP using direct viral detection, real-time reverse-transcription polymerase chain reaction (rtRT-PCR), and serology (microneutralization assay). Methods. RSV, other respiratory viruses, and bacteria were studied by conventional and molecular techniques in adults aged >= 18 years presenting with CAP to the healthcare facilities in Santiago, Chile from February 2005 through December 2007. Results. All 356 adults with CAP enrolled had an acute blood sample collected at enrollment, and 184 had a convalescent blood sample. RSV was detected in 48 cases (13.4%). Immunofluorescence assay and viral isolation each detected only 1 infection (0.2%), whereas rtRT-PCR was positive in 32 (8.9%) cases and serology was positive in 20 (10.8%) cases. CAP clinical characteristics were similar in RSV-infected and non-RSV-infected cases. RSV-specific geometric mean serum-neutralizing antibody titer (GMST) was significantly lower at admission in the 48 RSV-infected cases compared with 308 non-RSV-infected adults (GMST in log(2): RSV/A 8.1 vs 8.9, and RSV/B 9.3 vs 10.4; P < .02). Conclusions. RSV infection is frequent in Chilean adults with CAP. Microneutralization assay was as sensitive as rtRT-PCR in detecting RSV infection and is a good adjunct assay for diagnostic research. High RSV-specific serum-neutralizing antibody levels were associated with protection against common and severe infection. The development of a vaccine could prevent RSV-related CAP in adults.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/1605
Referências
  1. Avendano LF, 2003, J CLIN MICROBIOL, V41, P4879, DOI 10.1128/JCM.41.10.4879-4882.2003
  2. Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953
  3. CANE PA, 1992, J VIROL METHODS, V40, P297, DOI 10.1016/0166-0934(92)90088-U
  4. Chen M, 2010, J IMMUNOL METHODS, V362, P180, DOI 10.1016/j.jim.2010.08.005
  5. CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
  6. Escobar C, 2009, J MED VIROL, V81, P340, DOI 10.1002/jmv.21399
  7. Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
  8. Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
  9. Falsey AR, 2002, J CLIN MICROBIOL, V40, P817, DOI 10.1128/JCM.40.3.817-820.2002
  10. Falsey AR, 2007, SEMIN RESP CRIT CARE, V28, P171, DOI 10.1055/s-2007-976489
  11. Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
  12. Garcia DF, 2007, PEDIATR PULM, V42, P66, DOI 10.1002/ppul.20546
  13. Harmon M, 1989, DIAGNOSTIC PROCEDURE, P631
  14. Henrickson KJ, 2007, PEDIATR INFECT DIS J, V26, pS36, DOI 10.1097/INF.0b013e318157da6f
  15. Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077
  16. Johansson N, 2010, CLIN INFECT DIS, V50, P202, DOI 10.1086/648678
  17. Johnstone J, 2008, CHEST, V134, P1141, DOI 10.1378/chest.08-0888
  18. JONAS D, 1995, J CLIN MICROBIOL, V33, P1247
  19. Larranaga C, 2000, J MED VIROL, V60, P342, DOI 10.1002/(SICI)1096-9071(200003)60:3<342::AID-JMV14>3.0.CO;2-0
  20. Maass M, 1998, ATHEROSCLEROSIS, V140, pS25, DOI 10.1016/S0021-9150(98)00117-8
  21. Marcos MA, 2009, CURR OPIN INFECT DIS, V22, P143, DOI 10.1097/QCO.0b013e328328cf65
  22. Marcos MA, 2006, ANTIVIR THER, V11, P351
  23. Piedra PA, 2003, VACCINE, V21, P2448, DOI 10.1016/S0264-410X(03)00098-7
  24. Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4
  25. Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791
  26. Templeton KE, 2005, CLIN INFECT DIS, V41, P345, DOI 10.1086/431588
  27. Terrosi C, 2009, EPIDEMIOL INFECT, V137, P1684, DOI 10.1017/S0950268809002593
  28. TJHIE JHT, 1994, J CLIN MICROBIOL, V32, P11
  29. Vila-Corcoles A, 2009, RESP MED, V103, P309, DOI 10.1016/j.rmed.2008.08.006
  30. Walsh EE, 2004, J INFECT DIS, V189, P233, DOI 10.1086/380907

Coleções
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - HC/InCor